Therefore, increasing evidence showed that MAS-associated AOSD/sJIA had higher levels of IL-18 when compared to patients with no MAS association, IL-18BP or equivalent, which are suggested as a potential therapeutic option to neutralize IL-18 for MAS-associated conditions [95,120,126,127,128]. Here, IL18 is linked to macrophage activation syndrome.